Braf V600e Mutation Positive Metastatic Melanoma Therapeutics
1. Braftovi patent expiration
Treatment: Indicated in combination with binimetinib for the treatment of melanoma with a braf mutation; Braftovi is a kinase inhibitor indicated in combination with cetuximab and mfolfox6, for the treatment of ...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8501758 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(4 years from now) | |
| US8541575 | ARRAY BIOPHARMA INC | 3,4-diarylpyrazoles as protein kinase inhibitors |
Feb, 2030
(4 years from now) | |
| US8946250 | ARRAY BIOPHARMA INC | 3,4-diarylpyrazoles as protein kinase inhibitors |
Jul, 2029
(3 years from now) | |
| US9593099 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(4 years from now) | |
| USRE49556 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Feb, 2030
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9850229 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(4 years from now) | |
| US9850230 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(4 years from now) | |
| US9763941 | ARRAY BIOPHARMA INC | Method of treating melanoma by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate |
Nov, 2032
(6 years from now) | |
| US10005761 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(4 years from now) | |
| US9314464 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Jul, 2031
(5 years from now) | |
| US10258622 | ARRAY BIOPHARMA INC | Method of treating colorectal cancer by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)pheny1)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl) carbamate |
Nov, 2032
(6 years from now) | |
| US9474754 | ARRAY BIOPHARMA INC | Pharmaceutical combinations comprising a B-RAF inhibitor, and EGFR inhibitor and optionally a PI3K-α inhibitor |
Aug, 2033
(7 years from now) | |
| US9387208 | ARRAY BIOPHARMA INC | Pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate |
Nov, 2032
(6 years from now) | |
| US9593100 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-826) | Apr 08, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jun 27, 2023 |
| Orphan Drug Exclusivity(ODE-194) | Jun 27, 2025 |
| New Indication(I-928) | Oct 11, 2026 |
| New Indication(I-957) | Dec 20, 2027 |
| Orphan Drug Exclusivity(ODE-445) | Oct 11, 2030 |
Drugs and Companies using ENCORAFENIB ingredient
NCE-1 date: 27 June, 2022
Market Authorisation Date: 27 June, 2018
Dosage: CAPSULE
How can I launch a generic of BRAFTOVI before it's drug patent expiration?
More Information on Dosage
BRAFTOVI family patents
2. Zelboraf patent expiration
Treatment: Treatment of patients with unresectable or metastatic melanoma with brafv600e mutation as detected by an fda approved test
ZELBORAF's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8143271 | HOFFMANN LA ROCHE | NA |
Jun, 2026
(5 months from now) | |
| US7863288 | HOFFMANN LA ROCHE | NA |
Jun, 2029
(3 years from now) | |
| US8741920 | HOFFMANN LA ROCHE | Process for the manufacture of pharmaceutically active compounds |
Jul, 2030
(4 years from now) | |
| US7504509 | HOFFMANN LA ROCHE | Compounds and methods for development of Ret modulators |
Oct, 2026
(9 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8470818 | HOFFMANN LA ROCHE | NA |
Aug, 2026
(6 months from now) | |
| US9447089 | HOFFMANN LA ROCHE | Compositions and uses thereof |
Jun, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 17, 2016 |
| Orphan Drug Exclusivity(ODE) | Aug 17, 2018 |
| Orphan Drug Exclusivity(ODE-13) | Aug 17, 2018 |
| M(M-184) | Aug 31, 2019 |
| New Indication(I-757) | Nov 06, 2020 |
| Orphan Drug Exclusivity(ODE-158) | Nov 06, 2024 |
Drugs and Companies using VEMURAFENIB ingredient
NCE-1 date: 18 August, 2015
Market Authorisation Date: 17 August, 2011
Dosage: TABLET
More Information on Dosage
ZELBORAF family patents